Clinical practice. Chronic hepatitis C infection.

  title={Clinical practice. Chronic hepatitis C infection.},
  author={Hugo R. Rosen},
  journal={The New England journal of medicine},
  volume={364 25},
  • H. Rosen
  • Published 22 June 2011
  • Medicine
  • The New England journal of medicine
This article reviews the evaluation and initial management of chronic hepatitis C infection, with particular attention to the use of new directly acting antiviral agents in treatment regimens. 

Figures and Tables from this paper

Hepatitis C infection: Updates on treatment guidelines.
New treatment guidelines for the evaluation and management of patients with HCV infection are reviewed, offering sustained virologic response rates of over 95%, fewer adverse reactions, and shorter durations of therapy.
Impact of Sofosbuvir‐Based Therapy on Liver Transplant Candidates with Hepatitis C Virus Infection
Sofosbuvir use in patients with decompensated cirrhosis may be associated with reduced liver transplant waitlist mortality and reduced need for transplant.
Hepatitis B and C among patients with hidradenitis suppurativa: a population‐based study
Hidradenitis suppurativa is a chronic inflammatory condition related to multiple systemic diseases and infections that affects the immune system and contributes to central nervous system inflammation.
Systematic review: cost‐effectiveness of direct‐acting antivirals for treatment of hepatitis C genotypes 2‐6
The availability of direct‐acting antivirals (DAAs) has dramatically changed the landscape of hepatitis C virus (HCV) therapy; however, the cost and budget requirements for DAA treatment have been
Assessment of alcohol histories obtained from patients with liver disease: opportunities to improve early intervention
Early assessment and documentation of alcohol consumption is therefore essential, and recommended in both general practice and hospital settings.
Hepatitis C Virus: Gastrointestinal Features
Liver failure due to hepatitis C is the most common indication for liver transplantation in the United States, and no vaccine is currently available.
The impact of adherence and an intervention program on patient outcomes and costs in chronic hepatitis C infection
The impact of adherence and an intervention program on patient outcomes and costs in chronic hepatitis C infection and the need for further research into this topic is investigated.
Topic Review: Newly FDA Approved Medications for the Treatment of Hepatitis and an Algorithm for Treatment of Hepatitis C Genotype 1
This advancement begins a new dawn in the treatment of HCV and provides HCV Genotype1 patients with the greatest opportunity yet to successfully clear the hepatitis C virus.
Morbidity and Mortality Among Community-Based People Who Inject Drugs With a High Hepatitis C and Human Immunodeficiency Virus Burden in Chennai, India
We observed high mortality and liver disease progression associated primarily driven by untreated HIV and chronic hepatitis C as well as alcohol use in a cohort of PWID in India. Interventions to
Hepatitis C Virus Infection: Looking for Interferon Free Regimens
An overview of the clinical results recently reported for the treatment of hepatitis C virus infection with interferon-free regimens, focusing on the most promising new compounds and combinations is provided.


Diagnosis, management, and treatment of hepatitis C: An update
This document has been approved by the AASLD, the Infectious Diseases Society of America, and the American College of Gastroenterology.
Peginterferon and ribavirin for chronic hepatitis C.
A 44-year-old woman with chronic hepatitis C has intermittent fatigue and persistent elevations in serum alanine aminotransferase levels. Treatment with peginterferon and ribavirin is recommended.
A step forward in therapy for hepatitis C.
  • J. Hoofnagle
  • Medicine, Biology
    The New England journal of medicine
  • 2009
Not until the discovery of the hepatitis C virus (HCV) were the effects of interferon understood; treatment resulted in a decrease in HCV RNA levels, which led to a sustained absence of the virus.
Mixing the right hepatitis C inhibitor cocktail.
Treatment of chronic hepatitis C in patients with decompensated cirrhosis.
  • G. Everson
  • Medicine, Biology
    Reviews in gastroenterological disorders
  • 2004
In the absence of a virologic cure, maintenance therapy with peginterferon may slow disease progression and reduce the rate of clinical decompensation.
Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance.
High-risk sexual or iatrogenic exposures may be important contemporary risk factors for HCV infection and the spontaneous viral clearance rate in this contemporary study was similar to that reported for past studies of transfusion-associated HCVs.
Natural history of hepatitis C.
Interferon for Decreasing the Incidence of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C
The incidence of HCC is decreased not only in the patients who respond to interferon completely, accompanied by the loss of HCV RNA from serum, but also in those who obtain normal levels of aminotransferase while HCV persists after interferons.